(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 12.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.29%.
Veracyte's revenue in 2026 is $517,145,000.On average, 15 Wall Street analysts forecast VCYT's revenue for 2026 to be $46,630,972,469, with the lowest VCYT revenue forecast at $43,606,784,738, and the highest VCYT revenue forecast at $48,432,295,009. On average, 14 Wall Street analysts forecast VCYT's revenue for 2027 to be $52,537,117,348, with the lowest VCYT revenue forecast at $49,179,998,807, and the highest VCYT revenue forecast at $55,457,214,540.
In 2028, VCYT is forecast to generate $57,942,674,137 in revenue, with the lowest revenue forecast at $52,748,476,764 and the highest revenue forecast at $60,713,389,486.